Robert Zimmer

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

Robert Zimmer, Hugo R. Scherbarth, Oscar Rillo et al. · Annals of the Rheumatic Diseases · 2012 · 160 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial

Sylviane Muller, Fanny Monneaux, Nicolas Schall et al. · Arthritis & Rheumatism · 2008 · 118 citations

Life Sciences, Immunology, Pharmacotherapy +16

Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase‐A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.

Ivan Berlin, Robert Zimmer, Thiede Hm et al. · British Journal of Clinical Pharmacology · 1990 · 81 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers

Ivan Berlin, Robert Zimmer, A. Cournot et al. · Clinical Pharmacology & Therapeutics · 1989 · 57 citations

Medicine, Pharmacology, Pharmacotherapy +15

Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo

Juliette Frémaux, Claire Venin, Laura Mauran et al. · Nature Communications · 2019 · 52 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13